Progress and Challenges in the Management of Congenital Cytomegalovirus Infection

Overview

Journal Clin Pract

Publisher MDPI

Specialty General Medicine

Date 2024 Nov 25

PMID 39585019

Authors

Weronika Szulc

Natalia Szydlowska

Julia M Smyk

Anna Majewska

Affiliations

Soon will be listed here.

Abstract

Congenital cytomegalovirus (CMV) infection is the most common intrauterine viral infection with a significant impact on the foetus and newborn. Current diagnostic practice includes serological testing for specific antibodies, but there are no global screening protocols. Maternal CMV screening is often performed in conjunction with antenatal ultrasound. While most infections are asymptomatic, severe cases can lead to long-term disability or death. Antiviral therapies, mainly ganciclovir and valganciclovir, are reserved for symptomatic patients, especially those with central nervous system involvement. Although effective, these treatments are associated with significant side effects such as neutropenia and hepatotoxicity. Foscarnet and cidofovir are used as alternatives, but their efficacy and safety require further study in paediatric patient populations. The effectiveness of passive prophylaxis is still uncertain. The lack of universally accepted guidelines for diagnosis, treatment, and prevention and the risk of serious side effects highlight the need for continued research. This review evaluates current therapeutic strategies, discusses their efficacy and associated risks, and highlights the need for innovative approaches to improve outcomes for affected neonates.

References

Nishida K, Morioka I, Nakamachi Y, Kobayashi Y, Imanishi T, Kawano S . Neurological outcomes in symptomatic congenital cytomegalovirus-infected infants after introduction of newborn urine screening and antiviral treatment. Brain Dev. 2015; 38(2):209-16. DOI: 10.1016/j.braindev.2015.08.003. View

Kakei Y, Morioka I, Imai T, Itohara K, Yano I, Takahashi N . Assessment of patients' characteristics associated with the efficacy and safety of oral valganciclovir treatment for infants with symptomatic congenital cytomegalovirus disease. J Infect Chemother. 2024; 30(10):971-977. DOI: 10.1016/j.jiac.2024.03.006. View

Matthews T, Boehme R . Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988; 10 Suppl 3:S490-4. DOI: 10.1093/clinids/10.supplement_3.s490. View

Nigro G, Sali E, Anceschi M, Mazzocco M, Maranghi L, Clerico A . Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites. J Matern Fetal Neonatal Med. 2004; 15(5):325-9. DOI: 10.1080/14767050410001701349. View

Shim G . Treatment of congenital cytomegalovirus infection. Clin Exp Pediatr. 2023; 66(9):384-394. PMC: 10475861. DOI: 10.3345/cep.2022.01032. View

Suganuma E, Oka A, Sakata H, Adachi N, Asanuma S, Oguma E . 10-year follow-up of congenital cytomegalovirus infection complicated with severe neurological findings in infancy: a case report. BMC Pediatr. 2018; 18(1):369. PMC: 6260854. DOI: 10.1186/s12887-018-1348-8. View

Lazzarotto T, Blazquez-Gamero D, Delforge M, Foulon I, Luck S, Modrow S . Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in Screening and Management From a Panel of European Experts. Front Pediatr. 2020; 8:13. PMC: 7006044. DOI: 10.3389/fped.2020.00013. View

Chiopris G, Veronese P, Cusenza F, Procaccianti M, Perrone S, Dacco V . Congenital Cytomegalovirus Infection: Update on Diagnosis and Treatment. Microorganisms. 2020; 8(10). PMC: 7599523. DOI: 10.3390/microorganisms8101516. View

van Leeuwen E, Rengerink K, Pajkrt E . Hyperimmune globulin to prevent congenital CMV infection. N Engl J Med. 2014; 370(26):2543-4. DOI: 10.1056/NEJMc1405377. View

10.

Nigro G, La Torre R, Anceschi M, Mazzocco M, Cosmi E . Hyperimmunoglobulin therapy for a twin fetus with cytomegalovirus infection and growth restriction. Am J Obstet Gynecol. 1999; 180(5):1222-6. DOI: 10.1016/s0002-9378(99)70620-4. View

11.

Chatzakis C, Ville Y, Makrydimas G, Dinas K, Zavlanos A, Sotiriadis A . Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. Am J Obstet Gynecol. 2020; 223(6):870-883.e11. DOI: 10.1016/j.ajog.2020.05.038. View

12.

Smiljkovic M, Le Meur J, Malette B, Boucoiran I, Minsart A, Lamarre V . Blood viral load in the diagnostic workup of congenital cytomegalovirus infection. J Clin Virol. 2019; 122:104231. DOI: 10.1016/j.jcv.2019.104231. View

13.

Amir J, Wolf D, Levy I . Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr. 2010; 169(9):1061-7. DOI: 10.1007/s00431-010-1176-9. View

14.

Enders G, Daiminger A, Bader U, Exler S, Enders M . Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol. 2011; 52(3):244-6. DOI: 10.1016/j.jcv.2011.07.005. View

15.

DAlberti E, Rizzo G, Khalil A, Mappa I, Pietrolucci M, Capannolo G . Counseling in fetal medicine: Congenital cytomegalovirus infection. Eur J Obstet Gynecol Reprod Biol. 2024; 295:8-17. DOI: 10.1016/j.ejogrb.2024.01.037. View

16.

Whitley R, Cloud G, Gruber W, Storch G, Demmler G, Jacobs R . Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1997; 175(5):1080-6. DOI: 10.1086/516445. View

17.

Exler S, Daiminger A, Grothe M, Schalasta G, Enders G, Enders M . Primary cytomegalovirus (CMV) infection in pregnancy: Diagnostic value of CMV PCR in saliva compared to urine at birth. J Clin Virol. 2019; 117:33-36. DOI: 10.1016/j.jcv.2019.05.015. View

18.

Kimberlin D, Aban I, Peri K, Nishikawa J, Bernatoniene J, Emonts M . Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial. J Pediatr. 2024; 268:113934. DOI: 10.1016/j.jpeds.2024.113934. View

19.

Hughes B, Clifton R, Rouse D, Saade G, Dinsmoor M, Reddy U . A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. N Engl J Med. 2021; 385(5):436-444. PMC: 8363945. DOI: 10.1056/NEJMoa1913569. View

20.

. A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection. J Reprod Immunol. 2012; 95(1-2):73-9. DOI: 10.1016/j.jri.2012.05.002. View